Glucagon-like peptide-1 (GLP-1) receptor agonists have evolved from a breakthrough diabetes treatment to a multi-indication therapeutic powerhouse, driven by strong clinical efficacy, broad indications, and a large potential patient base.
What makes GLP-1 receptor agonists so highly successful?
GLP-1 receptor agonists, targeting G protein-coupled receptors (GPCRs) widely expressed across human cell types, bind endogenous GLP-1 to regulate blood sugar, suppress appetite, slow gastric emptying, and boost satiety. These mechanisms underpin their success in treating diabetes, obesity, cardiovascular diseases, and even neurodegenerative conditions.
Novel Directions: Multi-Target GLP-1 Therapies
While GLP-1 receptor agonists alone may see efficacy plateau at higher doses in diabetic patients, multi-target strategies offer new potential. These combine GLP-1 agonists with other peptides (e.g., glucagon [GCG], GIP) for greater weight loss and metabolic benefits, with candidates/drugs targeting GLP-1R/GIPR, GLP-1R/GCGR, and GLP-1R/GIPR/GCGR pathways in Phase II/III trials or already approved.